Efficacy of adefovir-based combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B virus infection

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6325-6332

  Lee, Yun Bin ^a   Lee, Jeong Hoon ^a   Choi, Won Mook ^a   Cho, Young Youn ^a   Yoo, Jeong Ju ^a   Lee, Minjong ^a   Lee, Dong Hyeon ^a   Cho, Yuri ^a   Yu, Su Jong ^a   Kim, Yoon Jun ^a   Yoon, Jung Hwan ^a   Kim, Chung Yong ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE; CREATININE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; VALINE; VIRUS DNA;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; SEROLOGY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS RESISTANCE;

ADENINE; ADULT; AGED; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84887463731     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01742-13     Document Type: Article

References (40)

1. Beasley RP. 1988. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
2. McMahon BJ. 2004. The natural history of chronic hepatitis B virus infection. Semin. Liver Dis. 24(Suppl 1):17-21.
3. Hadziyannis SJ, Papatheodoridis GV. 2006. Hepatitis B e antigennegative chronic hepatitis B: natural history and treatment. Semin. Liver Dis. 26:130-141.
4. Liaw YF. 2006. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir. Ther. 11:669-679.
5. European Association for the Study of the Liver. 2012. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 57:167-185.
6. Lok AS, McMahon BJ. 2009. Chronic hepatitis B: update 2009. Hepatology 50:661-662.
7. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 351:1521-1531.
8. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL, Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M. 2003. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722.
9. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
10. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, Pham B, Ungar WJ, Einarson TR, Heathcote EJ, Krahn M. 2010. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139:1218-1229.
11. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. 2009. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleosidenaive patients is rare through 5 years of therapy. Hepatology 49:1503-1514.
12. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ. 2006. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44:1656-1665.
13. Lok AS, McMahon BJ. 2007. Chronic hepatitis B. Hepatology 45:507-539.
14. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. 2008. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2:263-283.
15. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, Zoulim F. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 46:531-538.
16. Yatsuji H, Hiraga N, Mori N, Hatakeyama T, Tsuge M, Imamura M, Takahashi S, Fujimoto Y, Ochi H, Abe H, Maekawa T, Suzuki F, Kumada H, Chayama K. 2007. Successful treatment of an entecavirresistant hepatitis B virus variant. J. Med. Virol. 79:1811-1817.
17. Kurashige N, Ohkawa K, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hosui A, Miyagi T, Ishida H, Tatsumi T, Kanto T, Takehara T, Hayashi N. 2009. Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. Antivir. Ther. 14:873-877.
18. Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS. 2012. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/ lamivudine-resistant hepatitis B virus with or without adefovir resistance. J. Med. Virol. 84:424-430.
19. Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. 2012. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig. Dis. Sci. 57:1358-1365.
20. Delaney WE, IV, Yang H, Miller MD, Gibbs CS, Xiong S. 2004. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob. Agents Chemother. 48:3702-3710.
21. Seigneres B, Martin P, Werle B, Schorr O, Jamard C, Rimsky L, Trepo C, Zoulim F. 2003. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 47:1842-1852.
22. Chevaliez S, Bouvier-Alias M, Laperche S, Hezode C, Pawlotsky JM. 2010. Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification. J. Clin. Microbiol. 48:3641-3647.
23. Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C. 2009. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J. Viral Hepat. 16:279-285.
24. Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG, Kim YJ, Yoon JH, Lee HS. 2011. Add-on adefovir is superior to a switch to entecavir as rescue therapy for lamivudineresistant chronic hepatitis B. Dig Dis. Sci. 56:2130-2136.
25. Park JW, Kim HS, Seo DD, Jang JS, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK. 2011. Long-term efficacy of entecavir in adefovir-refractory chronic hepatitis B patients with prior lamivudine resistance. J. Viral Hepat. 18:e475-e481.
26. D'Agostino RB, Jr. 1998. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat. Med. 17:2265-2281.
27. Chen J, Wang Z, Zhou B, Wang Y, Hou J. 2012. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy. Antivir. Ther. 17:71-79.
28. Lee SA, Cho YK, Lee KH, Hwang ES, Kook YH, Kim BJ. 2011. Gender disparity in distribution of the major hydrophilic region variants of hepatitis B virus genotype C according to hepatitis B e antigen serostatus. J. Med. Virol. 83:405-411.
29. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. 2007. Antiviral drugresistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46:254-265.
30. Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. 2009. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 50:727-734.
31. Zoulim F, Locarnini S. 2012. Management of treatment failure in chronic hepatitis B. J. Hepatol. 56(Suppl 1):S112-S122.
32. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297.
33. Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, Gibbs CS, Parvaz P, Werle B, Trepo C, Zoulim F. 2003. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39:1085-1089.
34. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712.
35. Liu Y, Wang C, Zhong Y, Chen L, Li X, Ji D, Wang H, Xin S, Zoulim F, Xu D. 2010. Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B. Antivir. Ther. 15:1185-1190.
36. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. 2006. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131:1253-1261.
37. Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve JP, Trepo C, Zoulim F. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398.
38. Shaw T, Bartholomeusz A, Locarnini S. 2006. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 44:593-606.
39. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. 2013. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J. Viral Hepat. 20:e37-e46.
40. Horberg M, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C, Jr, Klein D. 2010. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. J. Acquir. Immune Defic. Syndr. 53:62-69.